2021 Volume 80 Issue 5 Pages 259-262
The patient was a 66-year-old man. In June 2018, he was found to have elevated serum CEA in a medicalcheckup, and colonoscopy (CF) revealed a type I lesion in the rectum (Rs). He was diagnosed with adenocarcinoma on the basis of biopsy findings and was referred to our hospital. Thoracoabdominal computed tomographyshowed distant lymph node metastases, and Stage IV cancer was diagnosed as unresectable.From August 2018, 12 courses of FOLFOXIRI (5-fluorouracil/leucovorin + oxialiplatin + irinotecan) and Cetuximab therapy were administered, and 12 courses of maintenance therapy were administered. Complete remission (CR) was confirmed in September 2019. The patient was alive without recurrence for 34 months after theinitiation of chemotherapy. The findings from this case suggest that this treatment for unresectable rectal cancercan result in CR.
